Otsuka Holdings Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Makoto Inoue
- Full Time Employees
- 37,758
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 2-9 Kanda-Tsukasamachi Tokyo TY Japan 101-0048
- IPO Date
- Aug 3, 2012
- Website
- otsuka.com
- Similar Companies
- Business
- Otsuka Holdings Co., Ltd. (OTSKY) is a holding company engaged in the research, development, manufacturing, and marketing of pharmaceutical products, nutritional products, consumer products, and other healthcare-related offerings. The company operates through three main segments: Pharmaceuticals, Nutrition and Medical Care Products, and Other; its pharmaceutical portfolio includes branded prescription drugs such as Abilify for schizophrenia and bipolar disorder, Samsca for hyponatremia, and Reyataz for HIV treatment; nutritional products encompass oral rehydration solutions like Pocari Sweat and Calol for medical nutrition; consumer products feature energy drinks, cosmetics, and over-the-counter remedies under brands like Ponurin and Feel Beat; and other services include clinical trial support and electronic components for medical devices. Otsuka Holdings maintains global operations across Japan, North America, Europe, Asia, and other regions, serving healthcare providers, hospitals, pharmacies, and consumers. Founded in 1921 and headquartered in Tokyo, Japan, the company oversees subsidiaries such as Otsuka Pharmaceutical Co., Ltd. and Otsuka America Pharmaceutical, Inc., with no parent company. In recent developments within the last two years, Otsuka announced strategic partnerships for oncology drug development, including a collaboration with Bristol Myers Squibb on NK cell therapies; completed a major acquisition of a biotech firm focused on gene therapies in 2024; launched new CNS disorder treatments in Japan and the U.S.; and expanded its nutrition segment through a funding round supporting international market entry in emerging Asia-Pacific countries.
Otsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America
AstraZeneca (OTCMKTS:AZNCF) versus Otsuka (OTCMKTS:OTSKY) Financial Review
Otsuka Holdings Co., Ltd. (OTSKY) M&A Call Prepared Remarks Transcript
Santen Pharmaceutical (OTCMKTS:SNPHY) & Otsuka (OTCMKTS:OTSKY) Financial Review
Contrasting Otsuka (OTCMKTS:OTSKY) and Mayne Pharma Group (OTCMKTS:MAYNF)
Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
Recent Price Trend in Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) is Your Friend, Here's Why
Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) Is a Great Choice for 'Trend' Investors, Here's Why
Here's Why Momentum in Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTSKY) Should Keep going
US FDA approves Otsuka's kidney disease drug
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Otsuka Corporation (OSUKF) Q1 FY2025 Earnings Call Transcript
Otsuka Holdings Co., Ltd. (OTSKY) Q2 FY2024 Earnings Call Transcript
OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q2 2024